Farther Finance Advisors’s Amphastar Pharmaceuticals AMPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$28.1K Buy
1,088
+314
+41% +$6.79K ﹤0.01% 3880
2026
Q2
$15.7K Sell
774
-362
-32% -$7.3K ﹤0.01% 4141
2026
Q1
$23K Sell
1,136
-245
-18% -$5.99K ﹤0.01% 3558
2025
Q4
$37K Buy
1,381
+437
+46% +$11.3K ﹤0.01% 3009
2025
Q3
$25.2K Buy
944
+737
+356% +$19K ﹤0.01% 2880
2025
Q2
$4.75K Buy
207
+72
+53% +$1.79K ﹤0.01% 3376
2025
Q1
$3.82K Sell
135
-8
-6% -$256 ﹤0.01% 3167
2024
Q4
$5.31K Hold
143
– – ﹤0.01% 2641
2024
Q3
$6.93K Sell
143
-2
-1% -$88 ﹤0.01% 2515
2024
Q2
$5.58K Buy
145
+47
+48% +$1.95K ﹤0.01% 2350
2024
Q1
$4.26K Hold
98
– – ﹤0.01% 2141
2023
Q4
$6.06K Buy
98
+18
+23% +$946 ﹤0.01% 1865
2023
Q3
$3.68K Buy
80
+10
+14% +$546 ﹤0.01% 1626
2023
Q2
$4.02K Hold
70
– – ﹤0.01% 1507
2023
Q1
$2.63K Hold
70
– – ﹤0.01% 1539
2022
Q4
$1.96K Buy
+70
New +$2.03K ﹤0.01% 1457

Other funds holding AMPH

Farther Finance Advisors's AMPH Position: Q3 2026 in Review

Farther Finance Advisors increased its Amphastar Pharmaceuticals (AMPH) stake by 41% in Q3 2026, buying an estimated $6.79K and bringing the position to 1,088 shares worth $28.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3880.

Farther Finance Advisors first reported a position in AMPH in Q4 2022 and has held it in 16 quarters since. The position peaked at $37K in Q4 2025. 9 funds tracked by Wall St. Rank hold AMPH as of Q3 2026.

  • Farther Finance Advisors held 1,088 shares of Amphastar Pharmaceuticals worth $28.1K as of Q3 2026.
  • Farther Finance Advisors bought 314 Amphastar Pharmaceuticals shares in Q3 2026, an estimated $6.79K.
  • Amphastar Pharmaceuticals made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #3880 holding.
  • Farther Finance Advisors first reported a position in Amphastar Pharmaceuticals in Q4 2022 and has held it in 16 quarters since.
  • Farther Finance Advisors's Amphastar Pharmaceuticals position peaked at $37K in Q4 2025.
  • 9 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.